securities class action

Ramaco Resources faces securities lawsuit alleging false statements about Brook Mine operations. Investors who purchased stock July-October 2025 may join class action litigation.

Trip.com faces securities investigation after Chinese antitrust probe triggered 17% stock decline. Law firm evaluates potential shareholder losses from alleged misleading disclosures.

Corcept faces securities lawsuit over misleading relacorilant claims. FDA rejected the drug, triggering 50% stock decline and $3.6B market cap loss.

Kyndryl restated financials citing internal control weaknesses, triggering 55% stock decline and departures of CFO, General Counsel, and Comptroller. SEC investigating disclosure gaps.

UniQure faces securities lawsuit alleging material misrepresentations about its Huntington's Disease trial design and FDA approval status. Lead plaintiff deadline is April 13, 2026.

Mereo BioPharma faces securities lawsuit alleging misrepresentations about Phase 3 trial results for setrusumab, causing investor losses.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

Corcept faces securities lawsuit after FDA rejected its drug candidate, causing 50% stock drop. Investors must apply by April 21 for class action lead plaintiff status.

uniQure faces class action lawsuit over failing to disclose FDA rejection of AMT-130 drug candidate, causing 49% stock decline. Lead plaintiff deadline: April 13, 2026.

Securities class action filed against Ardent Health after November 2025 disclosure of $43M revenue decrease and undisclosed liability reserves. Stock fell 34%; lead plaintiff applications due March 9, 2026.

Fermi Inc. faces securities lawsuit alleging misleading statements about Project Matador AI data center. Stock fell 59% after primary tenant terminated $150M funding agreement.

Varonis Systems faces securities lawsuit alleging executives failed to disclose weakening renewal rates and overstated SaaS transition progress, leading to 48% stock decline and $3.8 billion market cap loss.

Rosen Law Firm investigates Nidec for accounting irregularities at China operations and potentially misleading investor disclosures. Stock fell 22.7% following announcement.

Rosen Law Firm sues Richtech Robotics for allegedly making false Microsoft partnership claims. Class action targets investors who bought stock January 27-29, 2026.

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.

Varonis Systems faces securities lawsuit alleging false statements about revenue projections during SaaS transition. Investor deadline for lead plaintiff status is March 9, 2026.

Vistagen faces securities lawsuit over misleading trial disclosures. Investors must nominate lead plaintiff by March 16, 2026 deadline.

Richtech Robotics faces securities lawsuit after overstating Microsoft partnership, causing 30% stock surge followed by 20% decline when Microsoft clarified limited engagement.

Kyndryl faces securities lawsuit after 55% stock plunge following disclosure of internal control weaknesses, delayed filings, executive departures, and SEC inquiry.

Fermi Inc. faces securities lawsuit alleging IPO misrepresentations about AI data center demand and undisclosed tenant risks. Stock fell 59% after primary tenant's $150M funding agreement termination.